Abstract
Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6069-6071 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 27 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 15 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Ruxolitinib in CMML: A case study of innovative trial design in a rare cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS